Key result
The plasma-diluted thrombin time assay is reported as a useful and easily implemented method to monitor oral direct thrombin inhibitors such as dabigatran.
Why the study?
Can plasma-diluted thrombin time be used to monitor dabigatran concentrations?
Can plasma-diluted thrombin time be used to monitor dabigatran concentrations?
Plasma-diluted thrombin time can be utilized as an easily implemented assay for monitoring dabigatran levels in clinical scenarios requiring it.
May aid lab monitoring of dabigatran in select scenarios; leaves open prospective validation before wider adoption.
New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs.
No takes yet. Share an insight, caveat, or question.
Avecilla et al. (2012) studied Dabigatran therapy. Plasma-diluted thrombin time (DTI assay) was evaluated. The plasma-diluted thrombin time assay is reported as a useful and easily implemented method to monitor oral direct thrombin inhibitors such as dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: